Growth through Asia Precision for Medicine is expanding its APAC footprint with new offices in Singapore and Japan in 2026, signaling regional growth and a need for localized support, regulatory navigation, and regional partner networks to accelerate biomarker-driven trials.

Leadership Expansion Recent hires in leadership roles across labs translational sciences and oncology clinical development indicate a push to strengthen biomarker expertise, oncology programs, and late-stage development capabilities, presenting opportunities to align with sponsors seeking advanced translational and clinical development leadership.

Biomarker-Driven Focus Positioned as a global leader in biomarker-driven clinical research, the company’s value proposition centers on integrated data sciences and lab capabilities to improve trial predictability, creating cross-sell opportunities with sponsors requiring biomarker strategy, companion diagnostics, and analytics.

Global Scale & Reach With 35 offices and over 2000 professionals, Precision for Medicine offers global trial execution and site-network support, enabling conversations with sponsors pursuing multi-region trials, diverse patient recruitment, and harmonized data management across programs.

Strategic Partnerships Recent press mentions and industry recognition, plus ongoing events participation, suggest avenues to partner on innovative health challenges, forum collaborations, and joint initiatives to demonstrate thought leadership and expand deal flow with pharma and biotech sponsors.